HDAC5 and breast cancer: Depletion, inhibition, or silencing of HDAC5 in breast cancer, cervical carcinoma, and melanoma cell lines, and in hepatocellular carcinoma cell lines under hypoxia delayed cell cycle progression, reduced cell proliferation, migration, invasion and survival, induced apoptosis and autophagy and increased sensitivity to the DNA damaging agents doxorubicin and cisplatin [8,23,94,95].